Clinical Study of Balloon Pulmonary Angioplasty for Patients With Chronic Thromboembolic Pulmonary Hypertension

Condition:   Chronic Thromboembolic Pulmonary Hypertension Intervention:   Procedure: Ballon pulmonary angioplasty Sponsor:   Li Xuyan Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

This study quantified QOL among Japanese CTEPH patients and investigated whether balloon pulmonary angioplasty (BPA) improved QOL. METHODS AND RESULTS: We calculated the QOL scores of 45 CTEPH patients using the European Quality of Life Five Dimension scale (EQ-5D). The mean QOL score among 12 of those 45 not involved in any therapy except supplemental oxygen at the time of initial measurement was 0.673 ± 0.251. QOL was measured before and after BPA for 17 patients, and the mean significantly improved (QOL from 0.741 ± 0.195 to 0.802 ± 0.160, p 
Source: Journal of Cardiology - Category: Cardiology Authors: Tags: J Cardiol Source Type: research
This study aims to determine outcomes for CTEPH patients undergoing pulmonary endarterectomy (PEA) or balloon pulmonary angioplasty (BPA) in specialist pulmonary hypertension unit with treatment modality determined by a multi-disciplinary heart team.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (403) Source Type: research
Condition:   Chronic Thromboembolic Pulmonary Hypertension Intervention:   Procedure: Ballon pulmonary angioplasty Sponsor:   Li Xuyan Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
The treatment of chronic thromboembolic pulmonary hypertension has expanded considerably. The ability to endarterectomize chronic thromboembolic material, the availability of pulmonary hypertension medical therapy to treat inoperable chronic thromboembolic pulmonary hypertension and/or residual pulmonary hypertension, and the rebirth of pulmonary balloon angioplasty have changed the management landscape. Patient selection requires a multidisciplinary evaluation at an experienced center. What is inoperable chronic thromboembolic pulmonary hypertension to one group may be operable chronic thromboembolic pulmonary hypertensio...
Source: Cardiology Clinics - Category: Cardiology Authors: Source Type: research
This study involved 45 CTEPH patients who underwent BPA with mean pulmonary artery pressure (mPAP) of 37.0 mmHg (all ≥ 25 mmHg). All patients underwent echocardiography and right-heart catheterization at baseline and 3 months after BPA. RV and RA remodeling was assessed as RV and the RA area, and RV systolic function was calculated by averaging peak speckle-tracking longitudinal strain of the RV free-wall (RV free-wall strain). Significant reverse remodeling in the right-sided heart was observed after BPA, resulting in improvement of mPAP and pulmonary vascular resistance (RV area: from 15.0 ±&thins...
Source: The International Journal of Cardiovascular Imaging - Category: Radiology Source Type: research
Balloon pulmonary angioplasty (BPA) has emerged as a novel treatment option for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and persistent pulmonary hypertension post pulmonary endarterectomy (PEA) when traditional treatment options fail. However, the availability of BPA is limited to relatively few centers internationally with a dearth of literature published to date. The purpose of this study is to evaluate the safety and effectiveness of BPA as a treatment modality for CTEPH at a national Canadian referral center.
Source: Journal of Vascular and Interventional Radiology : JVIR - Category: Radiology Authors: Tags: Scientific Session 28 Source Type: research
AbstractPurpose of reviewChronic thromboembolic pulmonary hypertension (CTEPH) is a major cause of precapillary pulmonary hypertension leading to right heart failure and death if left untreated. In addition to pulmonary endarterectomy, which is considered the standard of care, and specific drug therapy that is not however expected to offer relief from the mechanical component of the disease, the therapeutic options for CTEPH have expanded with the development of balloon pulmonary angioplasty (BPA). The purpose of this review is a better understanding and evaluation of BPA as a treatment option in CTEPH patients.Recent find...
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research
Abstract BACKGROUND: With advancements in neonatology, patients in the neonatal intensive care unit (NICU) are living in the hospital with complex life-limiting illnesses until their first birthday or beyond. As palliative care (PC) becomes a standard of care in neonatology, a level IV NICU developed an interdisciplinary PC team with the mission to ease the physical, mental, and moral distress of the patients, families, and staff. This case report highlights the teamwork and long-term palliative care and ultimately end-of-life care that an infant received by this dedicated NICU palliative care team. CLINICAL ...
Source: Advances in Neonatal Care - Category: Nursing Authors: Tags: Adv Neonatal Care Source Type: research
AbstractChronic thromboembolic pulmonary hypertension (CTEPH) is classified as Group-4 pulmonary hypertension caused by organized thrombi in pulmonary arteries. Pulmonary endarterectomy (PEA) has been shown to improve the symptoms and prognoses of patients with proximal CTEPH. The soluble guanylate cyclase stimulator (riociguat) is the sole FDA-licensed drug for the treatment of CTEPH, and guidelines recommend its use for patients with inoperable CTEPH or residual or recurrent pulmonary hypertension following PEA. Balloon pulmonary angioplasty (BPA) is a new procedure, but it is a promising alternative to PEA, especially i...
Source: Cardiovascular Intervention and Therapeutics - Category: Cardiology Source Type: research
Source: Cardiovascular Intervention and Therapeutics - Category: Cardiology Source Type: research
More News: Angioplasty | Baloon Angioplasty | Hypertension | Pulmonary Hypertension | Research | Study